Powder: -20°C for 3 years | In solvent: -80°C for 1 year
EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor targeting EGFR and CDK-2, demonstrating IC50 values of 89.6 nM for EGFR and 165.4 nM for CDK-2. It prompts apoptosis in MCF-7 cells and causes S phase cell cycle arrest, exhibiting substantial anti-cancer activity with an IC50 of 2.74 μM against MCF-7 cells [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor targeting EGFR and CDK-2, demonstrating IC50 values of 89.6 nM for EGFR and 165.4 nM for CDK-2. It prompts apoptosis in MCF-7 cells and causes S phase cell cycle arrest, exhibiting substantial anti-cancer activity with an IC50 of 2.74 μM against MCF-7 cells [1]. |
Molecular Weight | 468.55 |
Formula | C24H16N6OS2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
EGFR/CDK2-IN-4 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR inhibitor inhibit